548 F.Supp.3d 1225
S.D. Fla.2021Background
- Ranitidine (brand Zantac and generics) allegedly degrades into NDMA, a probable human carcinogen; FDA set an acceptable daily intake and ultimately requested withdrawal of ranitidine products.
- Plaintiffs filed an MDL with three master complaints: AMPIC (personal injury), ELC (consumer economic-loss class claims), and MMC (medical-monitoring class claims), alleging design-defect, failure-to-warn (including via expiration dates), packaging, storage/transport, and testing failures against brand, generic, distributor, and store-brand defendants.
- Generic defendants moved to dismiss under impossibility pre-emption (PLIVA v. Mensing; Mutual Pharmaceutical v. Bartlett) and Buckman; store-brand defendants moved to dismiss or strike similar claims; several foreign generics challenged personal jurisdiction.
- The court held hearings, analyzed federal drug regulation (NDA/ANDA, labeling, CBE/changes procedures, cGMP), and applied impossibility- and fraud-on-the-agency pre-emption doctrines.
- Court concluded (1) claims that seek to compel reporting/warnings through the FDA are pre-empted under Buckman as interpreted by Mink; (2) failure-to-warn, design-defect, and negligence claims against generic and store-brand defendants are pre-empted under Mensing/Bartlett because federal law imposes a duty of ‘‘sameness’’ the defendants could not independently breach; (3) all claims against generic and store-brand defendants were dismissed without leave to amend; special-appearance jurisdiction motion denied as moot.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Are claims that defendants failed to warn consumers by reporting to the FDA pre-empted? | These assert traditional state-law duties to warn; plaintiffs say they enforce state law, not the FDCA. | Such claims seek to regulate submissions to FDA and are pre-empted by Buckman (fraud-on-the-agency/preemption of state-law claims that intrude on federal regulatory scheme). | Pre-empted under Buckman (per Mink); dismissed. |
| Are failure-to-warn, expiration-date, packaging, storage/transportation, and testing claims against generic manufacturers pre-empted by impossibility (Mensing/Bartlett)? | Plaintiffs claim their theories allege discrete "sub-duties" (e.g., shorter expiration, different packaging, better storage/testing) that generics could have implemented consistent with federal law. | Generics invoke the federal duty of sameness (ANDA) and FDA rules precluding unilateral labeling/design changes; it is impossible to satisfy state duties without violating federal law. | Pre-empted under Mensing/Bartlett; claims dismissed. |
| Do the store-brand (private-label) defendants face non-preempted state-law claims for expiration dates/packaging/storage? | Store-brands are responsible as private-label distributors and owed state duties; their alleged failures fall within traditional state-law torts. | Store-brands lack authority under federal law to alter ANDA-mandated design/labels; same impossibility preemption bars state claims. | Pre-empted for same reasons as generics; claims dismissed. |
| Is the special-appearing non-U.S. generics' personal-jurisdiction challenge live? | Defendants contested jurisdiction. | Defendants sought dismissal for lack of jurisdiction. | Motion denied as moot because all substantive claims against generics were dismissed. |
| Should dismissal be with leave to amend? | Plaintiffs sought leave to replead narrower theories. | Defendants opposed; court cited prejudice, repeated failures, and futility. | Dismissal without leave to amend (futility and undue prejudice). |
Key Cases Cited
- Buckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341 (2001) (state-law fraud-on-the-agency claims pre-empted because they conflict with federal regulatory enforcement scheme)
- PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011) (generic manufacturers' federal duty of sameness can make state failure-to-warn duties impossible to satisfy)
- Mutual Pharm. Co. v. Bartlett, 570 U.S. 472 (2013) (design-defect claims against generics pre-empted where federal law forbids altering generic drug design)
- Wyeth v. Levine, 555 U.S. 555 (2009) (brand manufacturers could unilaterally use CBE process to strengthen warnings; no impossibility pre-emption without clear FDA prohibition)
- Mink v. Smith & Nephew, Inc., 860 F.3d 1319 (11th Cir. 2017) (interpreting Buckman to pre-empt certain FDA-reporting-based state claims)
- Drager v. PLIVA USA, Inc., 741 F.3d 470 (4th Cir. 2014) (state-law negligent-testing claims construed as part of overall failure-to-warn/design duties and pre-empted)
- Guarino v. Wyeth, LLC, 719 F.3d 1245 (11th Cir. 2013) (claims that are, at bottom, failure-to-warn are broadly pre-empted under Mensing)
- In re Darvocet, Darvon, & Propoxyphene Prods. Liab. Litig., 756 F.3d 917 (6th Cir. 2014) (derivative claims rise or fall with underlying claims; relevant for dismissal of survivorship/wrongful-death/unjust-enrichment counts)